Linezolid in the Starter Combination for Multidrug-Resistant Tuberculosis: Time to Move on to Group Four?

Linezolid (LNZ), a group 5 antituberculous drug (unclear efficacy), was used in the starter regimens of 23 adults with multidrug-resistant tuberculosis. The LNZ-containing regimens were effective in achieving culture conversions and relapse-free outcomes. The most frequent LNZ-related side effect wa...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Open forum infectious diseases Jg. 2; H. 4; S. ofv175
Hauptverfasser:	Grard, Soazic, Catho, Gaud, Valour, Florent, Bouaziz, Anissa, Perpoint, Thomas, Braun, Evelyne, Biron, François, Miailhes, Patrick, Ferry, Tristan, Chidiac, Christian, Souquet, Pierre-Jean, Couraud, Sébastien, Lina, Gérard, Goutelle, Sylvain, Veziris, Nicolas, Dumitrescu, Oana, Ader, Florence
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	United States Oxford University Press 01.12.2015
Schlagworte:	Bacteriology Brief Reports Immunology Life Sciences Microbiology and Parasitology Virology neuropathy ethionamide linezolid multidrug-resistant tuberculosis
ISSN:	2328-8957, 2328-8957
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!